Alunbrig: A kinase inhibitor

Healthcare professionals recommend using the drug Brigatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Alunbrig is the trade name of the drug Bringatinib. Bringatinib is a tyrosine kinase inhibitor with in vitro activity at clinically achievable concentrations against multiple kinases, including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3, well as EGFR deletion and point mutations. Alunbrig tablets come in the strengths of 180 mg, 90 mg and 30 mg for oral administration. The active ingredient in the tablets is Brigatinib, with inactive ingredients lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica.
Alunbrig price is reasonable, and one can find this medicine from certified generic medicine suppliers. For further information about this medicine, contact us on toll-free no. 18008891064.

https://www.indianpharmanetwork.in/alunbrig-brigatinib/ Tweet